ATE423559T1 - Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren - Google Patents
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatorenInfo
- Publication number
- ATE423559T1 ATE423559T1 AT02717766T AT02717766T ATE423559T1 AT E423559 T1 ATE423559 T1 AT E423559T1 AT 02717766 T AT02717766 T AT 02717766T AT 02717766 T AT02717766 T AT 02717766T AT E423559 T1 ATE423559 T1 AT E423559T1
- Authority
- AT
- Austria
- Prior art keywords
- combination therapy
- ppar modulators
- absorption inhibitors
- glucose absorption
- ppar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28142901P | 2001-04-04 | 2001-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE423559T1 true ATE423559T1 (de) | 2009-03-15 |
Family
ID=23077253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02717766T ATE423559T1 (de) | 2001-04-04 | 2002-04-03 | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren |
Country Status (11)
Country | Link |
---|---|
US (3) | US20030045553A1 (de) |
EP (2) | EP2065044A1 (de) |
JP (1) | JP4590159B2 (de) |
CN (1) | CN100577175C (de) |
AT (1) | ATE423559T1 (de) |
CA (1) | CA2442917C (de) |
DE (1) | DE60231295D1 (de) |
ES (1) | ES2321815T3 (de) |
MY (1) | MY180762A (de) |
TW (1) | TWI330084B (de) |
WO (1) | WO2002080936A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE423559T1 (de) | 2001-04-04 | 2009-03-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren |
CN100384430C (zh) | 2001-04-04 | 2008-04-30 | 奥索-麦克尼尔药品公司 | 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗 |
US20090162342A1 (en) * | 2001-06-07 | 2009-06-25 | Sanomune Inc. | Therapeutic uses of glandular kallikrein |
EP1388352A1 (de) * | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
JP2004300102A (ja) * | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
US7601756B2 (en) * | 2003-06-06 | 2009-10-13 | Snowden Pharmaceuticals, Llc | Method of treatment for irritable bowel syndrome |
CA2530228A1 (en) * | 2003-06-27 | 2005-01-06 | Dr. Reddy's Research Foundation | Compositions comprising balaglitazone and further antidiabetic compounds |
US7691420B2 (en) * | 2003-09-23 | 2010-04-06 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
US20050239706A1 (en) * | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
EP1707195A4 (de) * | 2004-01-23 | 2007-06-20 | Japan Science & Tech Agency | Retinolsäureenthaltendes heilmittel für diabetes |
JP4901218B2 (ja) * | 2004-02-09 | 2012-03-21 | あすか製薬株式会社 | 併用医薬 |
NZ550340A (en) | 2004-03-17 | 2010-08-27 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle using a retinoid |
JP5010918B2 (ja) * | 2004-07-21 | 2012-08-29 | キッセイ薬品工業株式会社 | 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤 |
US7767682B2 (en) * | 2005-03-03 | 2010-08-03 | Glaxosmithkline Llc | Medicaments |
US20080280955A1 (en) * | 2005-09-30 | 2008-11-13 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
EP1785133A1 (de) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
WO2008096769A1 (ja) * | 2007-02-08 | 2008-08-14 | Daiichi Sankyo Company, Limited | 置換されたセルコスポラミド誘導体を含有する医薬 |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
US8666671B2 (en) * | 2007-07-05 | 2014-03-04 | Enhanced Pharmaceuticals, Inc. | Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
KR101516677B1 (ko) * | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
WO2010023594A1 (en) * | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
UA105216C2 (en) | 2009-04-16 | 2014-04-25 | Тайсо Фармасьютикал Ко., Лтд. | Pharmaceutical composition |
US20120115912A1 (en) * | 2009-07-10 | 2012-05-10 | Landreth Gary E | Rxr agonist compounds and methods |
BR112012007349A2 (pt) | 2009-10-02 | 2019-09-24 | Sanofi Sa | uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas. |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
KR101426180B1 (ko) | 2009-11-02 | 2014-07-31 | 화이자 인코포레이티드 | 디옥사-비시클로[3.2.1]옥탄-2,3,4-트리올 유도체 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
PL2543357T3 (pl) * | 2011-07-07 | 2018-08-31 | Holy Stone Healthcare Co.,Ltd. | Kompozycja do zastosowania w leczeniu i zapobieganiu zaburzeniom związanym ze stanem zapalnym |
US9451987B2 (en) | 2011-11-16 | 2016-09-27 | K2M, Inc. | System and method for spinal correction |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
CN102727477B (zh) * | 2012-06-14 | 2014-07-16 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治糖尿病药物中的应用 |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
CA3054962A1 (en) | 2017-03-09 | 2018-09-13 | Rick PAULS | Dosage forms of tissue kallikrein 1 |
RU2020124373A (ru) * | 2017-12-28 | 2022-01-28 | Юниверсити Оф Фукуи | Профилактический агент и/или терапевтический агент для катаракты, медицинский состав для предотвращения и/или лечения катаракты, применение ppar-активатора для тех же целей и глазные капли |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
JPH0253573A (ja) * | 1988-08-11 | 1990-02-22 | Nippon Riki Kk | ラチェットレンチの製造法 |
US5731299A (en) | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
CA2102591C (en) | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
JP2762903B2 (ja) | 1992-11-12 | 1998-06-11 | 田辺製薬株式会社 | ジヒドロカルコン誘導体及びその製法 |
JP2795162B2 (ja) | 1993-02-18 | 1998-09-10 | 田辺製薬株式会社 | ジヒドロカルコン誘導体及びその製法 |
JP2906978B2 (ja) * | 1993-02-25 | 1999-06-21 | 田辺製薬株式会社 | 血糖降下剤 |
US6046222A (en) | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
EP0859608B1 (de) | 1995-09-18 | 2004-02-11 | Ligand Pharmaceuticals, Inc. | Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten |
JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
TR199900056T2 (xx) | 1996-07-12 | 1999-04-21 | Smithkline Beecham P.L.C. | Leptin direncinin yeni tedavisi. |
PT850948E (pt) * | 1996-12-26 | 2002-08-30 | Tanabe Seiyaku Co | Derivados propiofenona e processo para a preparacao dos mesmos |
JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
JP4100734B2 (ja) | 1997-04-30 | 2008-06-11 | Sabicイノベーティブプラスチックスジャパン合同会社 | 熱可塑性樹脂組成物 |
KR20010013845A (ko) | 1997-06-18 | 2001-02-26 | 피터 기딩스 | 티아졸리딘디온 및 알파-글루코시다제 억제제를 사용한당뇨병의 치료 |
JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
BR9916795A (pt) * | 1998-11-20 | 2002-04-09 | Mitsubishi Chem Corp | Cristais de 5-{{6-( 2-fluorobenzil) oxi-2- naftil} metil} -2,4- tiazolidinodiona |
US6337426B1 (en) | 1998-11-23 | 2002-01-08 | Nalco/Exxon Energy Chemicals, L.P. | Antifoulant compositions and processes |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
WO2000065052A1 (en) | 1999-04-22 | 2000-11-02 | Habener Joel F | Bridge-1, a transcription factor |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
CZ303372B6 (cs) | 1999-08-31 | 2012-08-22 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát a farmaceutická kompozice s jeho obsahem a benzylpyrazolový meziprodukt |
AU6949900A (en) | 1999-08-31 | 2001-03-26 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
PE20010580A1 (es) | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
JP2001192375A (ja) * | 1999-10-29 | 2001-07-17 | Takeda Chem Ind Ltd | オキシイミノアルカン酸誘導体の結晶 |
TW558554B (en) | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
AR026414A1 (es) * | 1999-11-10 | 2003-02-12 | Takeda Pharmaceutical | Compuetos heterociclicos de 5 miembros que contienen nitrogeno |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
DK1333887T3 (da) | 2000-10-30 | 2006-11-13 | Ortho Mcneil Pharm Inc | Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler |
CN1238363C (zh) | 2000-12-28 | 2006-01-25 | 橘生药品工业株式会社 | 吡喃葡糖氧基吡唑衍生物及其在药物中的应用 |
ATE423559T1 (de) | 2001-04-04 | 2009-03-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren |
CN100384430C (zh) | 2001-04-04 | 2008-04-30 | 奥索-麦克尼尔药品公司 | 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗 |
-
2002
- 2002-04-03 AT AT02717766T patent/ATE423559T1/de not_active IP Right Cessation
- 2002-04-03 DE DE60231295T patent/DE60231295D1/de not_active Expired - Lifetime
- 2002-04-03 EP EP09075012A patent/EP2065044A1/de not_active Withdrawn
- 2002-04-03 CN CN02811137A patent/CN100577175C/zh not_active Expired - Lifetime
- 2002-04-03 ES ES02717766T patent/ES2321815T3/es not_active Expired - Lifetime
- 2002-04-03 CA CA2442917A patent/CA2442917C/en not_active Expired - Lifetime
- 2002-04-03 US US10/115,827 patent/US20030045553A1/en not_active Abandoned
- 2002-04-03 WO PCT/US2002/010538 patent/WO2002080936A1/en active Application Filing
- 2002-04-03 JP JP2002578975A patent/JP4590159B2/ja not_active Expired - Fee Related
- 2002-04-03 EP EP02717766A patent/EP1381361B1/de not_active Expired - Lifetime
- 2002-04-04 TW TW091106918A patent/TWI330084B/zh not_active IP Right Cessation
- 2002-04-04 MY MYPI20021224A patent/MY180762A/en unknown
-
2003
- 2003-03-24 US US10/395,502 patent/US20030199557A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,120 patent/US8278268B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20030045553A1 (en) | 2003-03-06 |
DE60231295D1 (de) | 2009-04-09 |
TWI330084B (en) | 2010-09-11 |
US20080096802A1 (en) | 2008-04-24 |
CN100577175C (zh) | 2010-01-06 |
CA2442917A1 (en) | 2002-10-17 |
ES2321815T3 (es) | 2009-06-12 |
CN1568190A (zh) | 2005-01-19 |
EP1381361A1 (de) | 2004-01-21 |
US20030199557A1 (en) | 2003-10-23 |
EP2065044A1 (de) | 2009-06-03 |
MY180762A (en) | 2020-12-08 |
US8278268B2 (en) | 2012-10-02 |
CA2442917C (en) | 2011-02-01 |
WO2002080936A1 (en) | 2002-10-17 |
JP4590159B2 (ja) | 2010-12-01 |
JP2004529915A (ja) | 2004-09-30 |
EP1381361B1 (de) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE423559T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren | |
ATE442148T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren | |
PT1333887E (pt) | Metodo de tratamento de desordens musculares | |
PL374865A1 (en) | Treatment of tnf alpha related disorders | |
PT1349856E (pt) | Compostos de isoindolina-1-ona activadores da glicocinase | |
IL194950A0 (en) | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
DE60035232D1 (de) | (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom | |
DE10339915A8 (de) | Entwicklungsverfahren, Substratbehandlungsverfahren und Substratsbehandlungseinrichtung | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
DE60322582D1 (de) | Oberflächenbehandlung von medizinischem gerät | |
NO20051521D0 (no) | Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt | |
CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
EA200500098A1 (ru) | Лекарственное средство и способ лечения патологического синдрома | |
NO20022087L (no) | Fremgangsmåte for behandling av diabetes | |
ATE350385T1 (de) | Neue aryl fructose-1,6-bisphosphatase inhibitoren | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
DK1429756T3 (da) | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer | |
NO20015772L (no) | Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff | |
NO20054700L (no) | Anvendelse av et fibrat og orlistat for behandling av fedme | |
DK1530462T3 (da) | 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens | |
SE0103276L (sv) | Anordning för administrering av salva till en hudyta | |
AU2003221350A1 (en) | Light amplifying device and method of manufacturing the device, light source device using the light amplifying device, light treatment device using the light source device, and exposure device using the light source device | |
IT1320192B1 (it) | Composizione terapeutica per la cura della psoriasi. | |
DK1366033T3 (da) | Kemiske forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |